Ultragenyx Pharmaceutical Inc. (RARE): Free Cash Flow
-$472.00M
Year ended 2025-12-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$472.00M | n/m | 2026-02-18, From 2025-01-01 |
| 2024-12-31 | -$421.00M | n/m | 2026-02-18, From 2024-01-01 |
| 2023-12-31 | -$519.00M | n/m | 2026-02-18, From 2023-01-01 |
| 2022-12-31 | -$496.59M | n/m | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | -$411.79M | n/m | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | -$176.12M | n/m | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | -$370.21M | n/m | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | -$294.64M | n/m | 2021-02-12, From 2018-01-01 |
| 2017-12-31 | -$256.64M | n/m | 2020-02-14, From 2017-01-01 |
| 2016-12-31 | -$171.16M | n/m | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | -$110.93M | n/m | 2018-02-21, From 2015-01-01 |
| 2014-12-31 | -$46.78M | n/m | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | -$31.61M | n/m | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | -$13.60M | n/a | 2015-03-27, From 2012-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$472.00M | n/m |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $136.42M | +436.8% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$93.89M | n/m |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $45.99M | -73.1% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $121.23M | -29.7% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $136.66M | -23.5% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | -$24.99M | n/m |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $156.80M | +338.0% |
| Opko Health, Inc. (OPK) | 2025-12-31 | -$190.82M | n/m |
Compare RARE, KNSA, AXSM, SUPN side by side · Screen every company in Pharmaceutical Preparations ↗